IPSC - Century Therapeutics Inc Stock Price, Fair Value and News

$1.10+0.05 (+4.76%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

IPSC Price Action

Last 7 days

-9.8%

Last 30 days

-12.7%

Last 90 days

-35.3%

Trailing 12 Months

-52.8%

IPSC RSI Chart

IPSC Valuation

Market Cap

93.5M

Price/Earnings (Trailing)

-0.72

Price/Sales (Trailing)

50.6

EV/EBITDA

-0.34

Price/Free Cashflow

-0.8

IPSC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

IPSC Fundamentals

IPSC Revenue

Revenue (TTM)

2.2M

Rev. Growth (Yr)

-5.19%

Rev. Growth (Qtr)

-7.73%

IPSC Earnings

Earnings (TTM)

-129.9M

Earnings Growth (Yr)

4.57%

Earnings Growth (Qtr)

-0.06%

IPSC Profitability

EBT Margin

-5849.98%

Return on Equity

-66.38%

Return on Assets

-33.42%

Free Cashflow Yield

-125.3%

IPSC Investor Care

Shares Dilution (1Y)

42.11%

Diluted EPS (TTM)

-1.92

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	6.6M	8.3M	10.3M	2.2M
2022	0	0	0	5.9M

Get all data in R, Python etc through our Historical Stock Data APIs

About Century Therapeutics Inc

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-102, a CAR-iT targeting CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-107, an iPSC-derived Nectin-4 CAR gamma delta T-cell therapy product candidate; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

CEO	Dr. Gregory Russotti Ph.D.
WEBSITE	centurytx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	163

Century Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Century Therapeutics Inc? What does IPSC stand for in stocks?

IPSC is the stock ticker symbol of Century Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Century Therapeutics Inc (IPSC)?

As of Fri Dec 20 2024, market cap of Century Therapeutics Inc is 93.53 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IPSC stock?

You can check IPSC's fair value in chart for subscribers.

Is Century Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether IPSC is over valued or under valued. Whether Century Therapeutics Inc is cheap or expensive depends on the assumptions which impact Century Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IPSC.

What is Century Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, IPSC's PE ratio (Price to Earnings) is -0.72 and Price to Sales (PS) ratio is 50.6. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IPSC PE ratio will change depending on the future growth rate expectations of investors.